Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Xencor Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Xencor şirketinin kazançları yıllık ortalama -37.3% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.7% oranında artan oldu. Gelirler yıllık ortalama 4.9% oranında artan oldu.

Anahtar bilgiler

-37.3%

Kazanç büyüme oranı

-36.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	4.9%
Özkaynak getirisi	-31.9%
Net Marj	-132.7%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27

Xencor: Standing Out With XmAb Technology

Feb 03

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Jan 05

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Nov 13

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Nov 10

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18

Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts

Aug 06

Gelir ve Gider Dağılımı

Xencor nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:XNCR Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	134	-177	58
31 Mar 24	162	-133	52
31 Dec 23	168	-126	52
30 Sep 23	145	-119	49
30 Jun 23	113	-128	49
31 Mar 23	98	-140	49
31 Dec 22	165	-55	46
30 Sep 22	297	30	45
30 Jun 22	289	22	43
31 Mar 22	327	109	41
31 Dec 21	275	83	39
30 Sep 21	163	-4	35
30 Jun 21	179	24	32
31 Mar 21	124	-64	30
31 Dec 20	123	-69	30
30 Sep 20	84	-83	29
30 Jun 20	71	-80	27
31 Mar 20	77	-61	26
31 Dec 19	157	27	24
30 Sep 19	165	36	23
30 Jun 19	172	49	24
31 Mar 19	153	39	23
31 Dec 18	41	-70	22
30 Sep 18	59	-45	21
30 Jun 18	30	-71	18
31 Mar 18	43	-53	17
31 Dec 17	46	-38	17
30 Sep 17	22	-55	16
30 Jun 17	30	-40	15
31 Mar 17	84	15	14
31 Dec 16	109	45	13
30 Sep 16	103	40	12
30 Jun 16	99	38	12
31 Mar 16	34	-18	12
31 Dec 15	28	-18	11
30 Sep 15	12	-27	10
30 Jun 15	9	-23	9
31 Mar 15	9	-19	8
31 Dec 14	10	-16	7
30 Sep 14	6	-19	4
30 Jun 14	8	-17	3
31 Mar 14	11	85	2
31 Dec 13	10	85	3

Kaliteli Kazançlar: XNCR şu anda kârlı değil.

Büyüyen Kar Marjı: XNCR şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: XNCR kârlı değildir ve zararlar son 5 yılda yılda 37.3% oranında artmıştır.

Büyüme Hızlandırma: XNCR 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: XNCR kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: XNCR hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -31.94% ) sahiptir.

Xencor Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Xencor, Inc. has filed a Follow-on Equity Offering.

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Consensus revenue estimates fall by 18%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Xencor: Standing Out With XmAb Technology

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Price target decreased by 7.0% to US$40.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Consensus revenue estimates increase by 19%

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Co-Founder notifies of intention to sell stock

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Consensus EPS estimates fall by 20%

Insufficient new directors

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder recently sold US$183k worth of stock

Consensus revenue estimates decrease by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improves as stock rises 15%

Senior VP & Chief Medical Officer recently sold US$101k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Price target decreased to US$50.13

Consensus revenue estimates increase by 40%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations